Auditory MMN EEG in TRD in Response to Ketamine

This observational trial (n=30) will investigate the neurocomputational model of ketamine treatment response predictions in treatment-resistant depression (TRD).

Conducted by Unity Health Toronto, the study aims to apply a validated computational model of mismatch negativity (MMN) to predict treatment response following ketamine infusions and distinguish its effects on suicidal ideation from mood improvements.

Participants, aged 18 to 65, diagnosed with major depressive disorder (MDD) and in a Major Depressive Episode, will receive ketamine treatment intravenously twice weekly for two weeks.

The primary outcome measures include clinical remission defined as MADRS <10 and a ≥ 50% reduction in suicidal ideation from baseline. Secondary outcomes involve modelling cognitive and behavioural mechanisms to their neural causes. The study started in October 2022 and is estimated to be completed by December 2024.

Topic Treatment-Resistant Depression Suicidality Depression
Compound Ketamine
Country Canada
Visit trial
Status Recruiting
Results Published No
Start date 03 October 2022
End date 31 December 2024
Design Open
Type Observational
Generation First
Participants 30
Sex All
Age 18- 65
Therapy No

Trial Details

To develop and test a neurocomputational model of ketamine treatment response predictions in TRD.

Trial Number NCT05464264

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.